5-Amino-1MQ

Third-Party Tested

Independent lab verified

Batch-Specific CoA

Publicly accessible

YPB.242

Reference number

5mg

Lyophilized vial

Origin

5-Amino-1MQ (5-amino-1-methylquinolinium) was developed as a selective inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that methylates nicotinamide and reduces NAD+ precursor availability. The compound was characterized by Neelakantan et al. at the University of Texas Health Science Center at San Antonio.

Research Lineage

Neelakantan et al. published the initial characterization in 2017, demonstrating effects on adipocyte size and lipid content in cell culture models. Subsequent work by Kilgore et al. investigated its effects in high-fat diet mouse models. NNMT has emerged as a target in metabolic research due to its upregulation in visceral adipose tissue and its role in NAD+ metabolism.

Mechanism of Action

5-Amino-1MQ inhibits NNMT, preventing the methylation of nicotinamide (a NAD+ precursor). This is proposed to increase intracellular NAD+ levels and shift the SAM/SAH methylation ratio. In adipocyte cell culture, NNMT inhibition has been observed to reduce lipid accumulation and alter fat cell differentiation markers. The compound is cell-permeable and selective for NNMT over other methyltransferases.

Structural Notes

Small molecule (not a peptide). Molecular formula: C10H11N2O+. Molecular weight: 173.21 Da. Quinolinium salt derivative.